



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/582,964	07/06/2000	KEITH B HOFFMAN	THUR-001	4643
24353 7590 11/30/2005 BOZICEVIC, FIELD & FRANCIS LLP 1900 UNIVERSITY AVENUE SUITE 200 EAST PALO ALTO, CA 94303			EXAMINER WANG, SHENGJUN	
			ART UNIT 1617	PAPER NUMBER

DATE MAILED: 11/30/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

09/582,964

Applicant(s)

HOFFMAN ET AL.

Examiner

Shengjun Wang

Art Unit

1617

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 12 September 2005.
- 2a) ☒ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 43,46,47,51 and 54-58 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 43,46,47,51 and 54-58 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____ |
| 2) <input type="checkbox"/> Notice of Draftsperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application (PTO-152) |
| 3) <input type="checkbox"/> Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)
Paper No(s)/Mail Date _____ | 6) <input type="checkbox"/> Other: _____ |

DETAILED ACTION

Receipt of applicants' amendments and remarks submitted September 12, 2005 is acknowledged.

Claim Rejections 35 U.S.C. 112

1. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 43, 46, 47, 51, 54-58 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The claimed methods are directed to a method of treating epilepsy, by administering a serine protease inhibitor. First, there is lack of written description as to the serine protease inhibitors in general. As noted in pages 6 to 7 in the specification, there are many kinds of proteases. The application provides written description to some of the protease inhibitors, but fails to provide sufficient written description commensurate with the scope herein claimed. Applicants merely define those ligands by their function, not by their structures. Attention is directed to *General Electric Company v. Wabash Appliance Corporation et al* 37 USPQ 466 (US 1938), at 469, speaking to functional language at the point of novelty as herein employed: the vice of a functional claim exists not only when a claims is wholly functional, if that is ever true, but when the inventor is painstaking when he recites what has already been seen, and then uses conveniently functional language at the exact point of novelty. Functional language at the point

Art Unit: 1617

of novelty, as herein employed by Applicants, is further admonished in *University of California v. Eli Lilly and Co.* 43 USPQ2d 1398 (CAFC 1997) at 1406: stating this usage does little more than outlin[e] goals appellants hope the recited invention achieves and the problems the invention will hopefully ameliorate. Applicants functional language at the point of novelty fails to meet the requirements set forth under 35 USC 112, first or second paragraph. Claims employing functional language at the point of novelty, such as Applicants, neither provide those elements required to practice the inventions, nor inform the public during the life of the patent of the limits of the monopoly asserted *General Electric Company v. Wabash Appliance Corporation et supra*, at 468.

It is note that the application does not define the genus of “serine protease inhibitors” or by structure, or by structure in conjunction with specific functional characteristics. The particular examples herein are distinct each from the others in their chemical structures. One of skilled artisan would not be able to envision the other “serine protease inhibitor” which would be useful in the claimed invention. The instant specification fails to provide descriptive information, such as definitive structural or function features of the claimed genus of “serine protease inhibitors” that would distinguish the claimed “serine protease inhibitors” from other molecules with the similar properties. Since the disclosure fails to describe the common contributes or characteristics that identify members of the genus, and because the genus is highly variant, the disclosure of certain “serine protease inhibitors” is insufficient to describe the genus. *Vas-Cath Inc. v. Mahurkar*, 19 USPQ 2d 1111, clearly states "applicant must convey with reasonable clarity to those skilled in the art that, as of the filing date sought, he or she was in possession of the invention. The invention is, for purpose of the ‘written description’ inquiry, whatever is now

Art Unit: 1617

claimed.” (see page 1117). The specification does not “clearly allow person of ordinary skill in the art to recognize that [he or she invented what is claimed.” (see Vas-Cath at page 1116). As discussed above, by reading the specification herein, the skilled artisan cannot envision the detailed chemical structure of the encompassed genus of serine protease inhibitors.

1. Claims 43, 46, 47, 51, 54-58 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for employ those protease inhibitors disclosed at pages 6-7 in the specification, does not reasonably provide enablement for other compounds which may function as serine protease inhibitors. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention commensurate in scope with these claims. The claimed invention define the compounds employed therein solely by its function, encompassing any compounds that may function as serine protease inhibitors. The instant specification fails to provide information that would allow the skilled artisan to practice the instant invention without undue experimentation. Attention is directed to *In re Wands*, 8 USPQ 2d 1400 (CAFC 1988) at 1404 where the court set forth the eight factor to consider when assessing if a disclosure would have required undue experimentation. The court recited eight factors:

- 1) the quantity of experimentation necessary,
- 2) the amount of direction or guidance provided,
- 3) the presence of absence of working examples,
- 4) the nature of the invention,
- 5) the state of the prior art,
- 6) the relative skill of those in the art,

Art Unit: 1617

7) the predictability of the art, and

8) the breadth of the claims.

The claim recites the employment of serine protease inhibitors. The application does not define the genus of “serine protease inhibitors” or by structure, or by structure in conjunction with specific functional characteristics. The particular examples herein are distinct each from the others in their chemical structures. One of skilled artisan would not be able to envision the other “serine protease inhibitor” which would be useful in the claimed invention. The instant specification fails to provide descriptive information, such as definitive structural or function features of the claimed genus of “serine protease inhibitors” The state of the prior art indicates that it is unpredictable as to the structures of serine protease inhibitors. Applicants fail to provide information allowing skilled artisan to ascertain these compounds without undue experimentation. In the instant case, only a limited number of “serine protease inhibitors” examples are set forth, thereby failing to provide sufficient working examples. It is noted that these examples are neither exhaustive, nor define the class of compounds required. The pharmaceutical art is unpredictable, requiring each embodiment to be individually assessed of physiological activity. The instant claims read on all “serine protease inhibitors”, necessitating an exhaustive search for the embodiments suitable to practice the claimed invention, absent undue experimentation.

Additionally, claims 51, 54-58 are rejected under 35 U.S.C. 112, first paragraph because applicants fail to set forth the criteria that define those situations wherein this pathology, epilepsy, could be prevented. Additionally, Applicant fails to provide information allowing the skilled artisan to ascertain these situations without undue experimentation. The claims read on

Art Unit: 1617

preventing all type onsets of epileptic seizures. In the instant case, no examples is set forth illustrating a situation where epilepsy is prevented, thereby failing to provide sufficient working examples. It is noted that these examples are not exhaustive. The pharmaceutical art is unpredictable, requiring each embodiment to be individually assessed for physiological activity. In the instant case, it is known in the art that many underline etiologies may cause epilepsy. There is no single drug known in the art can control all type s of seizures. See, e.g., The Merck Manual, pages 1366-1375 attached hereto. The instant claims read on preventing all type of epileptic seizure activity necessitating an exhaustive search for the embodiments suitable to practice the claimed invention. Applicants fail to provide information sufficient to practice the claimed invention, absent undue experimentation.

2. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

3. Claims 55 and 57 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

4. The term "like" in claims 55 and 57 is a relative term which renders the claim indefinite. The term "like" is not defined by the claim, the specification does not provide a standard for ascertaining the requisite degree, and one of ordinary skill in the art would not be reasonably appraised of the scope of the invention. The claims are indefinite as to the serine protease encompassed thereby.

Claim Rejections 35 U.S.C. 102

5. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(e) the invention was described in (1) an application for patent, published under section 122(b), by another filed in the United States before the invention by the applicant for patent or (2) a patent granted on an application for patent by another filed in the United States before the invention by the applicant for patent, except that an international application filed under the treaty defined in section 351(a) shall have the effects for purposes of this subsection of an application filed in the United States only if the international application designated the United States and was published under Article 21(2) of such treaty in the English language.

6. Claims 43, 46, 47, 51, 54-58 are rejected under 35 U.S.C. 102(e) as being anticipated by Strickland et al. (US 5,786,187, IDS).

7. Strickland et al. teach a method of treating, suppressing or preventing seizure, and/or epilepsy in human or animal by inhibiting the activity of protease, particularly, tPA with a tPA inhibitor. See, particularly, column 1, lines 55 to column 2, line 9, column 3, lines 17-28, column 11, lines 21-48 and the claims.

Response to the Arguments

Applicants' amendments and remarks submitted September 12, 2005 have been fully considered, but are unpersuasive.

Regarding the enablement of "serine protease inhibitor," applicants argue that "serine protease inhibitor is known in the art to refer to a class of compound that all inhibit serine protease. One of skill in the art can readily determine whether a given compound is a serine protease inhibitor by simply assaying that compound to determine whether it has serine protease inhibitory activity." The arguments are unpersuasive. It is noted that the specification merely gives one specific example for serine protease inhibitor, AEBSF. Page 6, line 28 states:

Art Unit: 1617

“Inhibitors of interest include ...” The examples disclosed therein are not described specifically as serine protease inhibitor, but protease inhibitors in general. The application provide no description as to the structural feature of the “class of compounds” having inhibitory activity for serine protease. An assay method alone does not satisfy the written description for the class of compounds possessing the inhibitory activity. Particularly apropos to the present application is the following statement by the Supreme Court in *Brenner v. Manson*, 333 U.S. 157, 148 USPQ 689, 696:

“ But a patent is not a hunting license. It is not a reward for the search, but compensation for its successful conclusion. '[A] patent system must be related to the world of commerce rather than to the realm of philosophy.'”

The data presented in the application merely supports the treating a host suffering from epilepsy with AEBSF, does not support for the broad scope herein claimed.

Regarding the rejections under 35 U.S.C. 102 over Strickland et al., note, Strickland et al. particularly claims method of treating seizure by inhibiting the protease herein. Therefore, practice the method disclosed by Strickland would effectively practice the claimed method. Applicants contend that no inhibitor was tested by Strickland. Applicants are questioning the operability of the cited US patent. Since every patent is presumed valid (35 U.S.C. 282), and since that presumption includes the presumption of operability (*Metropolitan Eng. Co. v. Coe*, 78 F.2d 199, 25 USPQ 216 (D.C.Cir. 1935), examiners should not express any opinion on the operability of a patent. Further, since in a patent it is presumed that a process if used by one skilled in the art will produce the product or result described therein, such presumption is not overcome by a mere showing that it is possible to operate within the disclosure without obtaining the

Art Unit: 1617

alleged product. In re Weber, 405 F.2d 1403, 160 USPQ 549 (CCPA 1969). It is to be presumed also that skilled workers would as a matter of course, if they do not immediately obtain desired results, make certain experiments and adaptations, within the skill of the competent worker.

8. **THIS ACTION IS MADE FINAL.** Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire **THREE MONTHS** from the mailing date of this action. In the event a first reply is filed within **TWO MONTHS** of the mailing date of this final action and the advisory action is not mailed until after the end of the **THREE-MONTH** shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than **SIX MONTHS** from the mailing date of this final action.


Any inquiry concerning this communication or earlier communications from the examiner should be directed to Shengjun Wang whose telephone number is (571) 272-0632. The examiner can normally be reached on Monday to Friday from 7:00 am to 3:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan, can be reached on (571) 272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications

Art Unit: 1617

may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).


SHENGJUN WANG
Shengjun Wang
Primary Examiner
Art Unit 1617